Ovarian Cancer and Caregivers |
Ovarian Cancer Treatment Survey
We understand that the manufacturer of AVASTIN, Hoffman-LaRoche, will be applying for approval from Health Canada in the near future for the use of AVASTIN for women with recurrent ovarian cancer. AVASTIN has been used by some doctors to treat recurrent ovarian cancer.
Bevacizumab, known by its brand name, AVASTIN targets a cancer cell protein called vascular endothelial growth factor (VEGF). This protein helps cancers to grow blood vessels, so they can get food and oxygen from the blood. Information about AVASTIN and related side effects can be found on line at http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment/cancer-drugs/bevacizumab
As a component of the approval process, Ovarian Cancer Canada has the opportunity to provide a patient submission which outlines the views of patients and their caregivers. This survey will gather the input of caregivers.
In this survey, the word 'treatment' refers to chemotherapy drugs only and does not refer to surgery or radiation.
Information provided in this survey will be synthesized to form our submission. At times, we may use 'quotes', however, no names or identifiers will be used that could reveal your identity.
This survey should take approximately 10 minutes to complete. Thank you for your support.
Bevacizumab, known by its brand name, AVASTIN targets a cancer cell protein called vascular endothelial growth factor (VEGF). This protein helps cancers to grow blood vessels, so they can get food and oxygen from the blood. Information about AVASTIN and related side effects can be found on line at http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment/cancer-drugs/bevacizumab
As a component of the approval process, Ovarian Cancer Canada has the opportunity to provide a patient submission which outlines the views of patients and their caregivers. This survey will gather the input of caregivers.
In this survey, the word 'treatment' refers to chemotherapy drugs only and does not refer to surgery or radiation.
Information provided in this survey will be synthesized to form our submission. At times, we may use 'quotes', however, no names or identifiers will be used that could reveal your identity.
This survey should take approximately 10 minutes to complete. Thank you for your support.